Sanofi Autoimmune Pipeline Grows As Market Weighs Valuation And Momentum [Yahoo! Finance]
Sanofi - American Depositary Shares (SNY)
US:NYSE Investor Relations:
sanofi.com/en/investors
Company Research
Source: Yahoo! Finance
Sanofi has secured global exclusive rights to Kali Therapeutics' trispecific antibody KT501 for autoimmune diseases, including a first in human program for rheumatoid arthritis. The company has also received Japanese approval for Dupixent in bullous pemphigoid, making it the first targeted therapy for this condition in Japan. These two developments come as Sanofi, ticker ENXTPA:SAN, trades around €77.77, with the share price showing a 1.1% return over the past week and a 13.0% return over five years. Over shorter periods, the stock has seen a 2.3% decline over 30 days, a 5.5% decline year to date, and a 21.7% decline over one year, which frames how the market has recently been treating the name. For investors watching Sanofi's immunology and specialty care efforts, KT501 expands the early stage pipeline while the new Dupixent indication highlights the focus on additional uses for existing products. How these moves translate into future clinical results and prescription trends w
Show less
Read more
Impact Snapshot
Event Time:
SNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNY alerts
High impacting Sanofi - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
SNY
News
- Sanofi (SNY) was downgraded by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from "hold (c-)" to "sell (d+)".MarketBeat
- Kali and Sanofi sign licence agreement for KT501 autoimmune disease antibody [Yahoo! Finance]Yahoo! Finance
- Press release: Availability of the Q1 2026 aide-mémoire [Yahoo! Finance]Yahoo! Finance
- Press release: Availability of the Q1 2026 aide-mémoireGlobeNewswire
- Press Release: Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoidGlobeNewswire
SNY
Sec Filings
- 3/24/26 - Form 6-K
- 3/10/26 - Form 6-K
- 3/4/26 - Form 6-K
- SNY's page on the SEC website